Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lawrence Lauridsen

Family Medicine Rock Springs, WY Doctor of Osteopathy

NPI 1386993400 CMS profile 1086049

3000 College Dr, Rock Springs, WY 82901

Open in the dashboard

General payments

$3,783

207 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lawrence Lauridsen of Rock Springs, WY is reported in the CMS Open Payments database as having received $3,783 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $781 40
2024 General $689 30
2023 General $638 33
2022 General $617 34
2021 General $464 30
2020 General $284 20
2019 General $310 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Lauridsen
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Lawrence Lauridsen were reported at $781. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Lawrence Lauridsen Family Medicine median Middle half National median
2019 $310 $150 $41–$543 $163
2020 $284 $120 $32–$415 $114
2021 $464 $137 $35–$551 $132
2022 $617 $137 $37–$512 $149
2023 $638 $149 $42–$545 $160
2024 $689 $156 $44–$560 $164
2025 $781 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $660 29 payments
  2. AbbVie, Inc. $336 14 payments
  3. Merck Sharp & Dohme Corporation $304 20 payments
  4. Amgen Inc. $281 18 payments
  5. Otsuka America Pharmaceutical, Inc. $262 14 payments
  6. Pfizer Inc. $254 14 payments
  7. Lundbeck LLC $227 11 payments
  8. Lilly USA, LLC $205 15 payments
  9. Corium, Inc. $205 9 payments
  10. GlaxoSmithKline, LLC. $165 11 payments
  11. Other $883 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,774 206 payments
  2. Education $9 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $375 16 payments
  2. BREZTRI $313 8 payments
  3. REXULTI Psychiatry $262 14 payments
  4. REXULTI Psychiatry $227 11 payments
  5. Azstarys $205 9 payments
  6. BELSOMRA $194 14 payments
  7. JANUVIA $194 14 payments
  8. UBRELVY $188 7 payments
  9. VERQUVO $186 11 payments
  10. STEGLATRO $181 13 payments
  11. Other $3,275 198 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 89 drugs

Part D claims

3,081

Median for Family Practice: 1,826

Drug cost

$308,407

Median for Family Practice: $120,094

Branded share of claims

24.1%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 99 $58,180
Ozempic Semaglutide Brand 31 $31,930
Jardiance Empagliflozin Brand 30 $29,814
Xarelto Rivaroxaban Brand 37 $25,254
Verquvo Vericiguat Brand 53 $25,227
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $20,887
Breo Ellipta Fluticasone/Vilanterol Brand 28 $18,105
Lurasidone Hcl Generic 19 $10,621
Rexulti Brexpiprazole Brand 13 $9,969
Xtampza Er Oxycodone Myristate Brand 11 $6,847

The 10 drugs with the highest cost, of 89 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$39,821

Medicare's payments for the services billed

Medicare patients

200

Average age 75

Services billed

550

120 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 37%
Diabetes 30%
COPD 27%
Depression 27%
Heart failure 23%
Alzheimer's or dementia 22%
Ischemic heart disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $103
$103 11 —
REXULTI
  • Lundbeck LLC $74
  • Otsuka America Pharmaceutical, Inc. $25
$99 13 —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $68
$68 — —
UBRELVY
  • AbbVie, Inc. $60
$60 — —
Azstarys
  • Corium, Inc. $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record